Tamara Lynne Aqui, DO
Internal Medicine · Riverside, CANPI 1992333447
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,946 of the $2,296 with a category attached, or 84.7%. It is spread thinly across 28 manufacturers, the largest accounting for just 8.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,668, more than ten times the $24 reported in 2021.
Across 80 payments — averaging $28.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$190
- AstraZeneca$184
- Seagen Inc.$181
- Pfizer$171
- GSK$140
- Regeneron Healthcare Solutions, Inc.$139
- plus $1K from 22 others
What the payments were for
- Food & beverage$1,94685%
- Education$35015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 5 | $190 |
| AstraZeneca(2 entities) | 7 | $184 |
| Seagen Inc. | 2 | $181 |
| Pfizer | 9 | $171 |
| GSK | 2 | $140 |
| Regeneron Healthcare Solutions, Inc. | 5 | $139 |
| Johnson & Johnson | 5 | $113 |
| Merck | 5 | $110 |
| Genentech USA, Inc. | 4 | $106 |
| Rigel Pharmaceuticals, Inc. | 1 | $104 |
| AbbVie | 4 | $104 |
| Astellas Pharma US Inc | 2 | $102 |
| Sobi, Inc | 3 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $87 |
| Puma Biotechnology, Inc. | 4 | $75 |
| Novartis | 2 | $56 |
| Pharmacosmos Therapeutics Inc. | 2 | $48 |
| Recordati_rare_diseases_inc. | 2 | $43 |
| Bayer | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Tersera Therapeutics LLC | 1 | $31 |
| Boehringer Ingelheim | 1 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Array Biopharma Inc | 2 | $23 |
| Lilly USA, LLC | 1 | $19 |
| Antares Pharma, Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,296 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Riverside
- Christopher SwansonRiverside$319K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.